Reports on study results indicating a medication prescribed for schizophrenia and manic phases of bipolar disorder shows promise as a cocaine addiction treatment.
Reports on a randomized controlled trial of HIV-infected men and women who, as a result of receiving selenium supplements, experienced lower HIV viral load and greater CD4 cell count.
Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.
Presents data on the length of stay in substance abuse treatment among people who were in treatment as a result of legal pressure as compared with those in treatment voluntarily.
Describes research with rats to better understand cocaine’s effect on the neural signaling in the learning circuits of the brain.
Reports on a study of men with co-occurring substance abuse and antisocial personality disorders and the potential benefit of judicially mandated addiction treatment.
Describes NIDA’s drug abuse and addiction research priorities for the use of the American Recovery and Reinvestment Act of 2009 funds.
Highlights a project in which nine research centers collaborate with criminal justice partners to test science-based tools for integrating drug abuse treatment in prisons and probation and parole programs.
Reports on a study investigating the effectiveness of a combined therapy of disulfiram and naltrexone for people who abuse cocaine and alcohol.
Describes research revealing that for up to 6 weeks after smokers quit, their brain cells have more nicotine-binding receptors than nonsmokers, which may explain the struggle to quit.